Devgen strengthens its Board of Directors

Ghent, Belgium, June 2, 2009 - Devgen (Euronext Brussels: DEVG) announces today that Gengest BVBA, represented by Mr. Rudi Mariën, and Mr. Orlando de Ponti have been appointed members of the Board of Directors. Mr Mariën is, through his investment company Biovest ComVa, an important shareholder of Devgen nv. He was the co-founder, reference shareholder and chairman of the biotech company Innogenetics. He brings to Devgen significant experience in the management of both private and public businesses. Rudi Mariën holds a degree in pharmaceutical sciences from the University of Gent, and is specialized in clinical biology. Mr. de Ponti gained important experience in the breeding and seed business working for the Dutch Ministry of Agriculture and as a Managing Director R&D of Nunhems B.V. Nunhems is a global seed company with important operations in India. He is the President of the International Seed Federation (ISF), and holds various other external functions. Mr. Orlando de Ponti graduated as Agricultural Engineer and as doctor at the Wageningen Agricultural University. Thierry Bogaert, Devgen's CEO and member of the board welcomes both Mr Mariën and Mr de Ponti to Devgen's board of Directors: "We are convinced their knowledge and many years of experience will contribute significantly to the Board and to the Company." Remi Vermeiren, chairman of the board added: " I am very pleased with this expansion of the board of Devgen. Both new directors will without doubt bring substantial added value to the development of Devgen: Mr Mariën as a dynamic entrepreneur and longterm investor with experience in biotechnology; Mr de Ponti with both scientific as commercial experience in seed and breeding." About Devgen Devgen's mission is to enable farmers to sustainably grow more food on less land, with less water, agrochemicals and labor. Devgen uses advanced biotechnology and molecular breeding technology to make high yielding seeds and crop protection solutions with a superior environmental profile. Devgen brings this technology to the market in the world's major food and feed crops through two complementary strategies: - Licensing Devgen technology for use in corn, cotton and soy and selected other crops in exchange for R&D funding, and milestone and royalty payments. - Producing and selling its premium hybrid seeds in major field crops such as rice, sunflower, sorghum, and pearl millet, in the Indian subcontinent and S.E. Asia. In its Crop Protection unit, Devgen develops a novel nematicide, an agro-chemical product that protects crops from damage by parasitic nematodes. Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore, Hyderabad (India) and Delaware (US) and employs more than 200 people. For more information please contact: Thierry Bogaert, CEO Wim Goemaere, CFO Tel. +32 9 324.24.24 Tel. +32 9324.24.24 or visit: This press release may contain forward-looking statements containing the words "anticipates", "expects" , "intends", "plans", "estimates", "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or achievements of Devgen to be materially different from any future results or achievements expressed or implied by such forward-looking statements. These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation. This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.